Document is current
Any future updates will be listed below
-
Authors
Katagiri, Seiichiro
Akahane, Daigo
Takeyama, Kunihiko
Sato, Norihide
Takayama, Nobuyuki
Ando, Jun
Nitta, Hideaki
Noguchi, Masaaki
Naganuma, Ken
Momose, Shuji
Tabayashi, Takayuki
Kizaki, Masahiro
Kawada, Hiroshi
Kikuti, Yara Yukie
Carreras, Joaquim
Nakamura, Naoya
Gotoh, Akihiko
- License Information
-
More Information
Article History
Received: 21 December 2024
Accepted: 28 February 2025
First Online: 10 March 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. The studies involving human participants were reviewed and approved by Tokyo Medical University. In this retrospective study, information disclosure was carried out through a public notice document.
: HK: Chugai Pharmaceutical Co., Asahi Kasei Pharma Co., Japan Blood Products Organization. (Research Funding), AG: Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd (Research funding), PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc. (Cunsulting fees), Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Sanofi K.K. (Honoraria)
